These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607 [TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131 [TBL] [Abstract][Full Text] [Related]
6. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933 [TBL] [Abstract][Full Text] [Related]
7. Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. Haynes LM; Tonkin J; Anderson LJ; Tripp RA J Virol; 2002 Jul; 76(14):6873-81. PubMed ID: 12072488 [TBL] [Abstract][Full Text] [Related]
8. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy. Bolger G; Lapeyre N; Dansereau N; Lagacé L; Berry G; Klosowski K; Mewhort T; Liuzzi M Can J Physiol Pharmacol; 2005 Feb; 83(2):198-213. PubMed ID: 15791294 [TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. Jafri HS; Chavez-Bueno S; Mejias A; Gomez AM; Rios AM; Nassi SS; Yusuf M; Kapur P; Hardy RD; Hatfield J; Rogers BB; Krisher K; Ramilo O J Infect Dis; 2004 May; 189(10):1856-65. PubMed ID: 15122522 [TBL] [Abstract][Full Text] [Related]
10. [Primary respiratory syncytial virus infection in mice]. Zou Y; Huang H; Xu J Zhonghua Jie He He Hu Xi Za Zhi; 2001 Aug; 24(8):484-6. PubMed ID: 11718040 [TBL] [Abstract][Full Text] [Related]
11. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Johnson TR; Graham BS Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270 [TBL] [Abstract][Full Text] [Related]
12. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. Zhang W; Tripp RA J Virol; 2008 Dec; 82(24):12221-31. PubMed ID: 18818323 [TBL] [Abstract][Full Text] [Related]
13. DSCG reduces RSV-induced illness in RSV-infected mice. Hashimoto K; Mori S; Hashimoto Y; Kaneko H; Ishibashi K; Ishioka K; Kawasaki Y; Peebles RS; Munakata M; Hosoya M; Suzutani T J Med Virol; 2009 Feb; 81(2):354-61. PubMed ID: 19107959 [TBL] [Abstract][Full Text] [Related]
14. Virus-specific IgE enhances airway responsiveness on reinfection with respiratory syncytial virus in newborn mice. Dakhama A; Lee YM; Ohnishi H; Jing X; Balhorn A; Takeda K; Gelfand EW J Allergy Clin Immunol; 2009 Jan; 123(1):138-145.e5. PubMed ID: 19056111 [TBL] [Abstract][Full Text] [Related]
15. An immunocompromised BALB/c mouse model for respiratory syncytial virus infection. Kong X; Hellermann GR; Patton G; Kumar M; Behera A; Randall TS; Zhang J; Lockey RF; Mohapatra SS Virol J; 2005 Feb; 2():3. PubMed ID: 15701174 [TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Groothuis JR; Simoes EA; Hemming VG Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741 [TBL] [Abstract][Full Text] [Related]
17. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317 [TBL] [Abstract][Full Text] [Related]
18. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988 [TBL] [Abstract][Full Text] [Related]
19. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271 [TBL] [Abstract][Full Text] [Related]
20. Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. Fischer JE; Johnson JE; Johnson TR; Graham BS J Infect Dis; 2000 Oct; 182(4):1029-38. PubMed ID: 10979896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]